Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Head & Neck 1Breast 1

Conditions

Melanoma 2Skin Neoplasms 1

Interventions

Ipilimumab 101pembrolizumab 94Nivolumab 87Cyclophosphamide 69fludarabine phosphate 55aldesleukin 52Interleukin-2 39Dacarbazine 35Vemurafenib 31fludarabine 30trametinib 29dabrafenib 29Temozolomide 28Whole-Body Irradiation 21Aminolevulinic Acid 21Carboplatin 20CTLA-4 Antigen 20Bevacizumab 20Radiotherapy 19Peripheral Blood Stem Cell Transplantation 19Radiosurgery 18Tacrolimus 17Mycophenolic Acid 17Paclitaxel 16HhAntag691 163-ingenyl angelate 16Busulfan 15Introns 14Antilymphocyte Serum 14encorafenib 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Toll-Like Receptor 1 × Dermatologic × Clear all
NCT01701674 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
13 enrolled 10 charts
Dermatologic

Melanoma, Skin Neoplasms

NCT00314106 2012-10-18

Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
26 enrolled 11 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡